Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-Current Debt (2018 - 2022)

Theravance Biopharma (TBPH) has disclosed Non-Current Debt for 5 consecutive years, with $396.1 million as the latest value for Q2 2022.

  • Quarterly Non-Current Debt rose 5.61% to $396.1 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $396.1 million through Jun 2022, up 5.61% year-over-year, with the annual reading at $371.4 million for FY2021, 0.41% changed from the prior year.
  • Non-Current Debt for Q2 2022 was $396.1 million at Theravance Biopharma, up from $384.2 million in the prior quarter.
  • The five-year high for Non-Current Debt was $396.1 million in Q2 2022, with the low at $217.7 million in Q2 2019.
  • Average Non-Current Debt over 5 years is $326.3 million, with a median of $373.9 million recorded in 2020.
  • The sharpest move saw Non-Current Debt decreased 4.46% in 2019, then skyrocketed 73.18% in 2020.
  • Over 5 years, Non-Current Debt stood at $229.5 million in 2018, then fell by 4.46% to $219.3 million in 2019, then soared by 70.03% to $372.9 million in 2020, then dropped by 0.41% to $371.4 million in 2021, then rose by 6.67% to $396.1 million in 2022.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $396.1 million, $384.2 million, and $371.4 million for Q2 2022, Q1 2022, and Q4 2021 respectively.